SPES Pharmaceuticals

Executive Summary

SPES Pharmaceuticals is a private biopharmaceutical company based in Plainsboro, New Jersey, founded in 2017 with a mission to develop improved drug formulations and delivery technologies that enhance patient safety, convenience, and compliance. The company's focus areas include anti-tumor, antiemetic, central nervous system (CNS), and pain management therapeutics. By leveraging proprietary delivery platforms, SPES aims to address key limitations of existing therapies, such as poor bioavailability, frequent dosing, and adverse side effects. While the company has not publicly disclosed specific pipeline candidates or clinical stages, its strategy centers on reformulating approved drugs or developing novel delivery systems to create differentiated products with competitive advantages.

Upcoming Catalysts (preview)

• Q3 2026IND filing for lead reformulated antiemetic candidate60% success
• Q2 2026Preclinical data release for pain management delivery platform50% success
• TBDLicensing or partnership deal for CNS program40% success